In vitro anticancer effects of alpelisib against PIK3CA‑mutated canine hemangiosarcoma cell lines

Marika Maeda, Kazuhiko Ochiai, Masaki Michishita, Masami Morimatsu, Hiroki Sakai, Nayuta Kinoshita, Motoharu Sakaue, Eri Onozawa, Daigo Azakami, Masami Yamamoto, Katsumi Ishioka, Takuya Sadahira, Masami Watanabe, Yoshikazu Tanaka

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Hemangiosarcoma (HSA) is a malignant neoplasm that occurs in humans and canines with a poor prognosis owing to metastatic spread, despite effective treatment. The frequency of spontaneous HSA development is higher in canines than in humans. Therefore, canine HSA is a useful model of intractable human disease, which requires early detec‑ tion and an effective therapeutic strategy. A high frequency of the p110α phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic subunit alpha (PIK3CA) mutations is detected in a comprehensive genome‑wide analysis of canine cases of HSA. The present cloned the full‑length cDNA of canine PIK3CA and identified a mutation in codon 1047 from canine cases of HSA and cell lines that were established from these. The enforced expression of the 1047th histidine residue (H1047) R or L mutants of canine PIK3CA in HeLa cells enhanced epidermal growth factor receptor (EGFR) signaling via Akt phosphorylation. PIK3CA mutant canine HSA cell lines exhib‑ ited the hyperphosphorylation of Akt upon EGF stimulation as well. Alpelisib, a molecular targeted drug against PIK3CA activating mutations, exerted a significant antitumor effect in canine PIK3CA‑mutated HSA cell lines. By contrast, it had no significant effect on canine mammary gland tumor cell lines harboring PIK3CA mutations. On the whole, the find‑ ings of the present study suggest that alpelisib may be highly effective against PIK3CA mutations that occur frequently in canine HSA.

Original languageEnglish
Article number84
JournalOncology reports
Issue number4
Publication statusPublished - Apr 2022


  • 5‑bisphosphate 3‑kinase catalytic subunit alpha
  • Akt
  • alpelisib
  • canine
  • hemangiosarcoma
  • mutation
  • p110α phosphatidylinositol‑4

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'In vitro anticancer effects of alpelisib against PIK3CA‑mutated canine hemangiosarcoma cell lines'. Together they form a unique fingerprint.

Cite this